Live Webinar - 8/19: Avoid the Pitfalls of Cannabis Investing
Email not displaying correctly?
The U.S. is the largest cannabis market in the world:
Represents 84% of world cannabis sales
Is estimated to be 10x larger than Canada’s
Remains largely untapped
Has potential for greater legalization in the near future
Multi-state state operators offer direct exposure to the U.S. cannabis market
Shouldn’t your cannabis ETF have exposure to U.S. cannabis multi-state operators?
Multi-State Operators (M.S.O.s)
are U.S. based companies directly involved in the legal production and distribution of cannabis in U.S. states where approved. As more states legalize cannabis for medical or recreational-use and as this fragmented industry evolves, M.S.O.s are believed to be a growth opportunity based on their ability to develop operational, distribution, marketing, and research and development efficiencies across state lines.
AdvisorShares Pure Cannabis ETF (YOLO)
is the only U.S.-listed ETF offering exposure to U.S. multi-state operators
is actively managed to keep up with a rapidly evolving cannabis industry
has flexibility to make portfolio changes as markets dictate
can invest in U.S. or Canadian stocks offering pure cannabis exposure
Learn More >
Trailing Total Returns - NAV (%)
As of Date:8/12/2020
Since Incept.
AdvisorShares Pure Cannabis ETF YOLO YES 1.23 11.90 37.08 10.86 -37.30 -34.70
ETFMG Alternative Harvest ETF MJ NO -23.14 -2.53 12.41 -17.01 -51.61 -50.49
Amplify Seymour Cannabis ETF CNBS NO -13.02 2.16 20.60 -4.28 -51.56 -49.36
Cambria Cannabis ETF TOKE NO -15.40 0.00 14.15 -7.57 -47.63 -46.04
The Cannabis ETF THCX NO -19.11 1.18 20.49 -10.61 -54.28 -50.66
No. American Marijuana Index --- --- -4.30 9.82 26.94 4.74 -42.57 -41.17
Common inception is 7/26/2019. Source: Morningstar.
Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than original cost. Returns less than one year are not annualized. For the most recent standardized month-end and quarter-end performance for the funds, click on the following respective ticker: YOLOMJCNBSTOKETHCX.
Learn More About Cannabis Investing & YOLO | Live AlphaCall
Join us
August 19 at 4:00 pm EDT 
Avoid the Pitfalls
of Cannabis Investing
This will be a live call.
We will be accepting your questions.
Join our webinar with YOLO portfolio manager Dan Ahrens and learn more about cannabis investing.

We Know Your Time Is Valuable 
We Are Here for You
  An AdvisorShares Investment Consultant can be reached at 1.877.843.3831 to discuss our actively managed ETF offerings. We are able to assist with special order handling to ensure that you receive the best trading execution.
to an ADVISORSHARES Portfolio Manager or Investment Consultant 

Connect with us:
Facebook Twitter LinkedIn
ADVISORSHARES |  1.877.843.3831 | | Electronic mail policy

-For Financial Intermediary Use Only - Not For Use With The Retail Public-
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting the Fund’s website at Please read the prospectus carefully before you invest.  Foreside Fund Services, LLC distributor.
There is no guarantee that the Fund will achieve its investment objective. An investment in the Fund is subject to risk, including the possible loss of principal amount invested. The prices of equity securities rise and fall daily. These price movements may result from factors affecting individual issuers, industries or the stock market as a whole. Shares of the Fund may trade above or below their net asset value (“NAV”). The trading price of the Fund’s shares may deviate significantly from their NAV during periods of market volatility. There can be no assurance that an active trading market for the Fund’s shares will develop or be maintained.In addition, equity markets tend to move in cycles which may cause stock prices to fall over short or extended periods of time. Other Fund risks include market risk, liquidity risk, large cap, mid cap, and small cap risk. Please see prospectus for details regarding risk.
YOLO Competitor Disclosure
The purpose of the information in this material is to provide Investors with a means to evaluate investment strategies of Cannabis Related funds as compared to AdvisorShares Pure Cannabis ETF (YOLO) It is the opinion of Advisorshares, the Fund's investment adviser, that all funds are managed differently and do not react the same to economic or market events. The investment objectives, strategies, policies or restrictions of other funds may differ and more information can be found in their respective prospectuses. Therefore, we generally do not believe it is possible to make direct fund to fund comparisons in an effort to highlight the benefits of a fund versus another similarly managed fund.
YOLO – The AdvisorShares Pure Cannabis ETF seeks long-term capital appreciation.  Gross Expense Ratio = 1.10%, Net Expense Ratio = 0.74%.
The Fund is actively managed and seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business and in derivatives or other instruments that have economic characteristics similar to such securities.
In addition to its investment in securities of companies that derive a significant portion of their revenue from the marijuana and hemp business, the Fund may invest in securities of companies that, in the opinion of the Advisor, may have current or future revenues from cannabis-related business or that are registered with the DEA specifically for the purpose of handling marijuana for lawful research and development of cannabis or cannabinoid-related products. The Fund will only invest in companies that engage in cannabis-related business that is permitted by national and local laws of the relevant jurisdiction, including U.S. federal and state laws.
The Fund will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology and life sciences industry group within the health care sector. The Advisor may use a variety of methods for security selection. As the Fund primarily focuses on certain industries, the Advisor intends to select companies with dominant positions in their respective markets, or those in unique positions for growth and expansion. In addition, the Advisor may invest the Fund’s assets in lesser-known companies that the Advisor believes have a unique opportunity for growth.
The Fund is non-diversified and may invest a greater percentage of its assets in a particular issuer than a diversified fund.
During the most recent fiscal year, the Fund’s portfolio turnover rate was 26% of the average value of its portfolio.
Creation units consist of 25,000 Shares.
CNBS – The Amplify Seymour Cannabis ETF seeks to provide investors capital appreciation. Gross Expense Ratio = 6.14% Net Expense Ratio = 0.75%.
The Fund is an actively managed ETF that seeks to provide investment exposure to global companies principally engaged in the emerging cannabis and hemp ecosystem across one of three classifications, which includes:
*   Cannabis/Hemp Plant (Pharmaceuticals/Biotechnology, Cultivation & Retail, Hemp Products and Cannabis-Infused Products)
*   Support (Agricultural Technology, Real Estate and Commercial Services)
*   Ancillary (Consumption Devices/Mechanisms, Investing & Finance, Technology & Media and Other Ancillary).
Under normal market conditions the Fund will invest at least 80% of its net assets (including investment borrowings) in the securities of companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem. Penserra Capital Management LLC (“Penserra” or the “Sub-Adviser”) serves as the investment sub-adviser to the Fund.
The Fund’s portfolio manager, Tim Seymour, will actively seek investment opportunities in securities fitting within one of these classifications through the use of information available in public regulatory filings, third-party research, meetings with company management, and other publicly available information.
The Fund will only directly invest in companies that engage in activities that are legal in the country where it is incorporated, as well as in the country or countries where its operations are conducted. The Fund will not hold direct ownership in any companies that engage in cannabis-related business unless permitted by national and local laws of the relevant jurisdiction, including United States (“U.S”) federal and state laws.  In order to be eligible for investment in the Fund’s portfolio a company’s equity securities must comply with the certain liquidity standards.
The Fund’s portfolio manager expects, under normal market circumstances, that the Fund’s portfolio will consist of 20 to 45 companies. These securities may be issued by small, medium and large capitalization companies operating in both emerging and developed market countries. The Fund may purchase equity securities that trade on U.S. or non-U.S. securities exchanges and in the securities of non-U.S. companies that ADRs or GDRs to list on certain exchanges.
The fund is considered non-diversified under the ’40 act.
During the fiscal year ended October 31, 2019, the Fund’s portfolio turnover rate was 23% of the average value of its portfolio.
Creation Units consist of 50,000 shares.
The Fund is distributed by Foreside Fund Services, LLC.
A prospectus can be obtained at
THCX – The Cannabis ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Innovation Labs Cannabis Index.  Gross Expense Ratio = 0.95%.  Net Expense Ratio = 0.75
The Fund will use a replication strategy to track the index. However, the Fund may utilize a representative sampling strategy with respect to the Index when a replication strategy might be detrimental to shareholders. The Fund will invest at least 80% of its total assets in the component securities of the Index by investing in exchange listed common stock or corresponding ADRs of Cannabis Companies.
The Index is a proprietary, rules-based index designed to track the performance of a portfolio of Cannabis Companies.
The initial universe of Index constituents consists of publicly listed Cannabis Companies that are involved in the legal cannabis industry.. A company has a business interest in the legal cannabis-based pharmaceutical and consumer wellness & product markets if a significant percentage (at least 50%) of its revenues are derived from such activity.  Cannabis Companies do not include companies that grow or distribute marijuana inside the U.S. (unless and until such time as the cultivation, production, or distribution of such marijuana or products become legal under U.S. federal law). Cannabis Companies may, however, include companies that have a business interest in the legal hemp-based pharmaceutical and consumer wellness & product markets within the United States.
The index provider eliminates from the Index Universe any Cannabis Company that it knows, based on the Cannabis Company’s publicly available information, to not be operating legally or invests in companies not operating legally. If, through their investment process, the Advisor or Subadvisor identifies or becomes aware that a particular company no longer meets the Fund’s definition of Cannabis Companies, the Fund will immediately sell that position.
The Index Universe is then screened to not include stocks that have a market capitalization below $100 million and stocks listed on the Canadian Securities Exchange (the “CSE”). The Index constituents must  be listed on exchanges that require compliance with all laws,  rules and regulations applicable to their business, including U.S. federal laws.
Constituents must also have traded at least 200,000 shares during the month of reconstitution. At the time of monthly reconstitution, the Index constituents are weighted according to their market capitalization with the individual weight of an Index constituent capped at eight percent (8.00%), with the excess weighting proportionately distributed between the remaining constituents. The Index is rebalanced and reconstituted monthly, effective at the close of trading on the second Friday of the month. The Fund is rebalanced and reconstituted in accordance with the Index
The fund is considered to be non-diversified under the ’40 act.  
Because the Fund is newly organized, portfolio turnover information is not yet available.
Creation Units consist of 25,000 shares.
The Fund is distributed by Capital Investment Group, Inc.
A prospectus can be obtained at
MJ – The ETFMG Alternative Harvest ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Alternative Harvest Index. Expense Ratio = 0.75%
The Fund uses a “passive” replication strategy or indexing approach to try to achieve its investment objective.  However, the Fund may utilize a representative sampling strategy with respect to the Index when a replication strategy might be detrimental to shareholders
The Index tracks the performance of the exchange-listed common stock (or corresponding ADRs  or GDRs) of companies across the globe, including U.S. companies, that (i) are engaged in the legal cultivation of cannabis, including industrial hemp, or the legal production, marketing or distribution of cannabis, including industrial hemp, products for medical or nonmedical purposes; (ii) engage in the lawful creation, marketing or distribution of prescription drugs that utilize cannabinoids as an active ingredient; (iii) trade tobacco or produce tobacco products, such as cigarettes, cigars or electronic cigarettes; (iv) produce cigarette and cigar components, such as cigarette paper and filters; or (v) engage in the creation, production and distribution of fertilizers, plant foods, pesticides or growing equipment to be used in the cultivation of cannabis or tobacco.
A Cannabis Company is considered to be primarily engaged in a line of business if it derives more than 50% of its revenue from such activity.
The Index only includes companies that are engaged exclusively in legal activities under applicable national and local laws, including U.S. federal and state laws. Companies, whose business activities are legal under state cannabis law, but not legal under federal cannabis law, are automatically ineligible for inclusion in the Index.
The Fund will invest at least 80% of its total assets, exclusive of collateral held from securities lending, in the component securities of the Index and in ADRs and GDRs based on the component securities in the Index (the “80% Policy”). The Fund may invest up to 20% of its total assets in securities that are not in the Index to the extent that the Fund’s investment adviser believes that such investments should help the Fund’s overall portfolio track the Index.
The fund is considered non-diversified.
For the fiscal year ended September 30, 2019, the Fund’s portfolio turnover rate was 71% of the average value of its portfolio
Creation Units consider of 50,000 shares.
The fund is distributed by ETFMG Financial LLC.
For a Prospectus go to
TOKE – The Cambria Cannabis ETF seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry. Gross Expense Ratio = 0.59%, Net Expense Ratio = 0.49%.
The Fund seeks to achieve its investment objective by investing, under normal market conditions, primarily in global equity securities that provide a broad exposure to the cannabis industry which include companies that (i) engage in or support the legal production, cultivation, and/or sale of cannabis, including marijuana and hemp, such as certain agribusiness, biotechnology, life sciences, pharmaceutical, retail, finance, and real estate companies, (ii) perform lawful research as to the medical and pharmaceutical applications of marijuana and cannabis extracts, including cannabinoids, or (iii) produce and develop devices, goods, and equipment related to the cannabis industry, including hemp and its legal derivatives (collectively, “Cannabis Companies”). To be identified as a Cannabis Company, Cambria must determine that a company derives a significant portion (i.e., at least 50%) of its revenue or profits from the legal sale, cultivation, production, or provision of cannabis-related products, services, or research.
Under normal market conditions, at least 80% of the value of the Fund’s net assets (plus borrowings for investment purposes) will be invested in Cannabis Companies.
The Fund will only invest in publicly-traded Cannabis Companies that operate in a jurisdiction where the Cannabis Companies’ cannabis-related business activities are legal under the national and local laws of the relevant jurisdiction, including U.S. federal and state laws. Accordingly, the Fund does not currently (directly or indirectly) invest in Cannabis Companies located in the U.S. if their cannabis-related business activities are illegal under U.S. federal law, even if such activities are legal under state law.
 While the Fund will target investing in approximately 20 to 50 of the top Cannabis Companies based on Cambria’s determination as to their exposure to the cannabis industry, the quantity of holdings in the Fund will be based on a number of factors, including the asset size of the Fund and the number of companies that satisfy Cambria’s quantitative measurements at any one time. Filters will be implemented to screen for companies that pass various market capitalization, and liquidity requirements.  The Fund’s portfolio will be rebalanced periodically, but no less frequently than annually, to meet Cambria’s internal target allocations, which are developed pursuant to Cambria’s quantitative strategy.
The fund is new and does not have information on portfolio turnover yet.
Creation Units consist of 50,000 shares.
The Fund is distributed by ALPS Distributors Inc.
For a Prospectus go to

Add to your address book to ensure delivery.


4800 Montgomery Lane, Ste. 150, Bethesda, MD 20814

Unsubscribe - Unsubscribe Preferences